Raleukin

Cat. No.:	HY-108841
CAS No.:	143090-92-0
Molecular Formula:	$C_{759}H_{1186}N_{208}O_{232}S_{10}$
Molecular Weight:	17257.6
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Raleukin (AMG-719) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin (AMG-719) is the first biological agent to block the pro-inflammatory effects[1][2].
IC_{50} & Target	IL-1
In Vivo	Combined Etanercept (5 mg/kg, ip) and Anakinra (100 mg/kg, ip. daily for 7 days) substantially improves marginal mass human islet engraftment in immunodeficient mice[2]. Raleukin (AMG-719) enhances tumor growth inhibition in mice receiving peptide vaccination and β-(1-3),(1-6)-D-glucan[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nat Nanotechnol. 2023 Dec 5.
- Circulation. 2021 Sep 14;144(11):893-908.
- Cell Metab. 2024 Jan 2;36(1):90-102.e7.
- Nat Commun. 2023 Jul 31;14(1):4600.
- Small Methods. 2023 Feb 26;e2201300.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Cvetkovic RS, et al. Anakinra. BioDrugs. 2002;16(4):303-11; discussion 313-4.

[2]. McCall M, et al. Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice. Am J Transplant. 2012 Feb;12(2):322-9.

[3]. Harnack U, et al. IL-1 receptor antagonist anakinra enhances tumour growth inhibition in mice receiving peptide vaccination and beta-(1-3),(1-6)-D-glucan. Anticancer Res. 2010 Oct;30(10):3959-65.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA